KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Change in Cash (2016 - 2025)

Historic Change in Cash for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to -$838.0 million.

  • AbbVie's Change in Cash rose 8573.13% to -$838.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 billion, marking a year-over-year increase of 7300.17%. This contributed to the annual value of -$7.3 billion for FY2024, which is 30177.14% down from last year.
  • Per AbbVie's latest filing, its Change in Cash stood at -$838.0 million for Q3 2025, which was up 8573.13% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, AbbVie's Change in Cash peaked at $5.3 billion during Q1 2024, and registered a low of -$5.9 billion during Q3 2024.
  • Over the past 5 years, AbbVie's median Change in Cash value was -$473.0 million (recorded in 2023), while the average stood at -$148.4 million.
  • Its Change in Cash has fluctuated over the past 5 years, first crashed by 53577.82% in 2021, then soared by 31096.39% in 2024.
  • Over the past 5 years, AbbVie's Change in Cash (Quarter) stood at -$2.4 billion in 2021, then decreased by 8.0% to -$2.6 billion in 2022, then skyrocketed by 82.02% to -$473.0 million in 2023, then tumbled by 266.38% to -$1.7 billion in 2024, then skyrocketed by 51.64% to -$838.0 million in 2025.
  • Its Change in Cash stands at -$838.0 million for Q3 2025, versus $1.3 billion for Q2 2025 and -$349.0 million for Q1 2025.